2010
Family outcomes
Perlick D, Kaczynski R, Rosenheck R. Family outcomes. 2010, 133-155. DOI: 10.1017/cbo9780511712265.009.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsFamily outcomesDrugsPharmaceutical companiesSpecific outcomesOutcomesStatistical analysisCliniciansExtrapyramidal side effects
Caroff S, Miller D, Rosenheck R. Extrapyramidal side effects. 2010, 156-172. DOI: 10.1017/cbo9780511712265.010.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersExtrapyramidal side effectsDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsSide effectsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisCliniciansConclusion and implications for practice and policy
Rosenheck R, Stroup T, Lieberman J. Conclusion and implications for practice and policy. 2010, 288-306. DOI: 10.1017/cbo9780511712265.018.Peer-Reviewed Original ResearchAntipsychotic TrialsMental health policy makersDouble-blind conditionsClinical Antipsychotic TrialsIntervention Effectiveness (CATIE) projectHealth policy makersAntipsychotic medicationAntipsychotic drugsKey treatmentComparative effectivenessMental healthSchizophreniaNational InstituteU.S. National InstituteMedicationsLandmark studiesPsychiatric researchersTrialsDrugsPharmaceutical companiesSpecific outcomesStatistical analysisClinicians
2001
Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System
Leslie D, Rosenheck R. Use of Pharmacy Data to Assess Quality of Pharmacotherapy for Schizophrenia in a National Health Care System. Medical Care 2001, 39: 923-933. PMID: 11502950, DOI: 10.1097/00005650-200109000-00003.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdultAntipsychotic AgentsComorbidityDelivery of Health Care, IntegratedDiagnosis, Dual (Psychiatry)FemaleGuideline AdherenceHumansMaleMental Health ServicesMiddle AgedNational Health ProgramsOutcome and Process Assessment, Health CarePatient CompliancePolypharmacyPractice Guidelines as TopicSchizophreniaUnited StatesUnited States Department of Veterans AffairsConceptsPatient Outcomes Research TeamLarger mental health systemMultiple antipsychotic medicationsAntipsychotic medicationPORT recommendationsSchizophrenia Patient Outcomes Research TeamVeterans AffairsHealth systemTotal weekly doseTreatment of schizophreniaPrescription drug recordsMental health systemHealth care systemGeneralized estimation equationsMultiple antipsychoticsNational Health SystemOlder patientsWeekly doseNational health care systemPharmacy dataComorbid depressionTreatment recommendationsDrug recordsMedicationsPatientsThe Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia
LESLIE D, ROSENHECK R. The Effect of Institutional Fiscal Stress on the Use of Atypical Antipsychotic Medications in the Treatment of Schizophrenia. The Journal Of Nervous And Mental Disease 2001, 189: 377-383. PMID: 11434638, DOI: 10.1097/00005053-200106000-00005.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseAntipsychotic AgentsBenzodiazepinesBudgetsClozapineComorbidityDepressive DisorderDrug CostsFemaleHealth Care CostsHealth FacilitiesHumansMaleMiddle AgedOlanzapinePirenzepinePractice Patterns, Physicians'Regression AnalysisRisperidoneSchizophreniaTreatment OutcomeUnited StatesUnited States Department of Veterans AffairsConceptsAtypical antipsychotic medicationsTreatment of schizophreniaAtypical antipsychoticsAntipsychotic medicationExpensive atypical antipsychotic medicationsVeterans AffairsPrescription drug recordsGeneralized estimation equationsDrug recordsPatientsReduced likelihoodAntipsychoticsMedicationsFacility characteristicsSchizophreniaAtypicalsFinal sampleTreatmentOlanzapineRisperidone
1998
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer J, Rosenheck R. Compliance With Medication Regimens for Mental and Physical Disorders. Psychiatric Services 1998, 49: 196-201. PMID: 9575004, DOI: 10.1176/ps.49.2.196.Peer-Reviewed Original ResearchConceptsMedication complianceCompliance rateMicroelectronic monitoringMedication regimensPhysical disordersPsychiatric treatmentMedication compliance ratesDiscontinuation of medicationMean compliance rateAntidepressant medicationPill countAntipsychotic medicationNonpsychiatric disordersPatient compliancePsychiatric disordersPatientsPsychiatric patientsClinician judgmentMedicationsDisordersRegimensLower ratesTreatmentReportPercent